Nas últimas décadas a apresentação clínica da gestação ectópica tem evoluído de uma situação risco iminente vida, com abordagem terapêutica unicamente cirúrgica, para um panorama intervenções menos invasivas e melhor prognóstico. Neste cenário, o Letrozol ganhado destaque, esse medicamento é inibidor aromatase terceira geração sido utilizado forma efetiva no tratamento ectópica. Diante disso, p...

Background: Hyper-androgenemia is one of the main clinical features of polycystic ovarian syndrome (PCOS). Letrozol is an aromatase inhibitor drug, which is co-administered with gonadotropins in most cases of PCOS, to improve ovulation. Aromatase has a critical role in catalyzing the conversion of androgens to estrogens and is responsible for keeping the homeostatic balance between them. Hence ...

Metastatic eyelid tumours are rare and account for less than 2% of all eyelid neoplasms. We report a case of metastatic breast carcinoma to the eyelid in a 60-year-old Chinese lady presenting with a 2-year history of enlarging, painless nodular lower eyelid swelling. The 1 cm diameter lesion was provisionally diagnosed as a sebaceous cyst. However the excision biopsy revealed a mucinous carcino...

the aim of this study was to investigate the effects of 12 weeks of walking on plasma levels of leptin in postmenopausal women with breast cancer. nineteen postmenopausal women with breast cancer (age: 55.05+2.7 years) who received surgery, chemotherapy and radiation-therapy and were receiving hormone therapy by letrozol were divided into two groups: control (n=8) and experimental (n=11). subje...

Objective: Targeted-drug-delivery based lipid nanoparticles has emerged as a new and effective approach in cancer chemotherapy. Here, we investigated the ability of folate-modified nanostructured lipid carriers (NLCs) to enhance letrozol (LTZ) efficacy in MCF-7 breast cancer cells. Methods: New formulations were evaluated regarding to particle size and scanning electron microscope (SEM) feature...

Aromatase inhibitors have emerged as an alternative endocrine therapy for the treatment of hormone sensitive breast cancer in postmenopausal women. The use of third-generation inhibitors represented by exemestane, letrozol and anastrozole is currently indicated. Anastrozole is a nonsteroidal compound and a potent selective inhibitor of the aromatase enzyme. Although a few studies have shown tha...